HairGenesis� Vision & Philosophy
Pattern hair loss is a common � but deeply debilitating struggle which, perhaps surprisingly, affects men and women in roughly equal percentages. When we first formed our company back in 1993 we recognized that the treatment options available were, to say the least, sub-optimal. There was Rogaine�, there were wigs / hair replacement systems, and there was hair transplant surgery. Rogaine� worked for some but was not without limitations and potential negative side effects. Wigs / hair systems could look great but required constant, costly upkeep. Plus, they were itchy and often caused the wearer�s hair to thin even further. In the proper hands, surgical hair transplantation was an effective solution � but quite expensive. And if the surgeon wasn�t also an artist, the results could look dreadful. So when we started HairGenesis� we vowed to bring something truly useful and demonstrably better to the marketplace.
To begin, and partnering with a highly gifted transplant surgeon, we spent many years also conducting FDA-regulated, IRB-monitored, placebo-controlled research testing a number of compounds and medical devices intended to advance the field. From this work we learned how proper research ought to be done. Thus, in 1994 when we turned our attention to the idea of creating a better, naturally-derived hair loss treatment product, we followed the same scientifically scrupulous methodology used to validate drug-based therapies. As we soon learned, by applying rigorous standards of scientific validation to our candidate compounds, we were almost alone in the hair loss treatment field. This distinction has only grown during the twenty-plus years we�ve spent developing and refining our HairGenesis� product line.
1993: Company formed. Original concept was to integrate state-of-the-art medical research with artistically-rendered surgical transplantation. Denver, CO-based parent company of HairGenesis� operated as a surgical hair restoration center for much of the 1990�s.
1994-98: Several, FDA-regulated, IRB-monitored studies undertaken. These included the use of autologous fibroblasts as an adjunctive tool to aid healing as well as the deployment of copper-based tripeptides intended to speed revascularization of the transplant tissue grafts. Studies were subsequently reduced to monograph form and submitted for peer-review and publication in the appropriate medical Journals.
1995: First Generation of HairGenesis� released. This occurred after ~18 months of on-site, open-label clinical research. Early HairGenesis� versions were based on glycosides of saw palmetto. Preliminary results showed good response to treatment.
1997: Generation Four HairGenesis� released and was the first version to combine topical application to the scalp with the oral form of the proprietary composition. Second onsite, open-label study undertaken. Results showed enhanced clinical outcome.
2000: Based on excellent response to treatment observed so far, Company elects to undertake third-party, placebo-controlled, double-blind clinical study. Note: This work constitutes the first example of a naturally-based hair loss treatment formulation tested under such conditions.
2002: Study concluded. Clinical outcome demonstrates safety and efficacy of proprietary Generation Five HairGenesis� formula. Results published in peer-reviewed, highly respected medical Journal: PubMed
2006: New Generation of HairGenesis� conceived and developed. This Generation designed to inhibit pathologic inflammation in the hair follicle while simultaneously blocking deleterious 5 alpha-reductase metabolism. Formulation noteworthy as the first dual-mechanism hair loss treatment created. Hypothesis subjected to rigorous placebo-controlled, triplicate validated basic science testing by third-party lab at State University of New York (SUNY).
2008: As previously, results from the SUNY research reduced to monograph form and submitted for peer-review. Monograph accepted for publication and reported in Evid Based Complement Alternat Med Journal: PubMed
2012: Another peer-reviewed paper published, this time in the well-respected Hair Therapy & Transplantation Journal: OMICS Group
2014: In a world-first, new Generation Seven HairGenesis� tested by University of Chicago against benchmark maximum-strength drug finasteride (Propecia� / Proscar�).
2016: As published in the Journal, Phytother Res. Generation Seven HairGenesis� outperformed finasteride in a number of key studies testing the ability of both compounds to ameliorate the gene expression markers linked to pattern hair loss and benign prostatic hyperplasia (BPH): PubMed
Present: At the present time, HairGenesis� represents a unique option in the hair loss treatment category. No other naturally-based product has backed up its performance claims with the sort of high level of scientific analysis, research, and validation noted herein. Accordingly, it is our viewpoint that HairGenesis� offers the safety of a natural product coupled with the scientific proof associated with the drug-based alternatives.
Future: What then of the future? Because pattern hair loss is considered a complex trait disorder, the opportunity to identify, target and modulate causative factors remains a compelling modus operandi. We shall pursue this approach in a reasoned, careful and painstaking manner. As such, we�ve every reason to hope that enhanced clinical outcomes shall remain not only possible, but likely.
A Word About The Founder Of HairGenesis�
Dr. Geno Marcovici became fascinated with hair from a young age. His father was a hair stylist, his mother, a manicurist. At the age of 24, he began losing his hair. Disheartened by the limited availability of viable treatment choices, he decided to turn his professional attention to the hair loss industry.
Beginning in 1988, Marcovici became involved with companies offering hair replacement systems, laser therapy, minoxidil therapy and surgical hair restoration. He learned about the pluses and minuses of each option by spending years observing how they worked for real people in the real world. In 2000, he obtained a doctorate in Molecular Biology, writing his dissertation on the subject of natural compounds and their putative utility in the setting of common pattern hair loss (Androgenetic Alopecia - AGA).
Over the past two decades, he has authored a number of well-respected, peer-reviewed and published studies in this branch of medicine. Likewise, he has participated as an expert reviewer in numerous university-based studies, including those testing naturally-based compounds. In 2014, after a great deal of study, Dr. Marcovici was awarded the title of �Board Certified Diplomate� by the American Association of Anti-Aging Health Providers.
Today, Dr. Marcovici continues to work diligently in this exciting scientific arena. His primary goal is to keep discovering, testing and bringing to market safe and highly effective solutions against pattern hair loss.